Pharmacogenomics of GPCR drug targets. Hauser et al.

Published: 10-01-2018| Version 1 | DOI: 10.17632/pr5v9t8z36.1
Contributors:
Alexander Hauser,
Madan Babu Mohan

Description

Summary Natural genetic variation in the human genome is a cause of individual differences in responses to medications and is an under-appreciated burden on public health. Although 108 G protein-coupled receptors (GPCRs) are the targets of 475 (~34%) FDA-approved drugs, the prevalence of genetic variation among GPCRs targeted by drugs is unknown. By analysing data from 68,496 individuals we find that GPCRs targeted by drugs show genetic variation within functional regions such as drug- and effector-binding sites in the human population. We experimentally show that certain variants of my-opioid and Cholecystokinin-A receptors could lead to altered or adverse drug response. By analysing drug prescription and sales data, we suggest that characterising GPCR variants could increase prescription precision, improving patients’ quality of life and relieve the economic and societal burden due to variable drug responsiveness.

Files